Resumen de Countering Public Health Threats
A toxin-neutralizing antibody intended to treat inhalation anthrax was among the products approved in fiscal year 2016 as part of the FDA’s Medical Countermeasures Initiative, which aims to protect the United States from chemical, biological, radiological, and nuclear threats as well as emerging infectious diseases such as Zika virus.
Legislation enacted in 2013 requires the agency to issue an annual update on its work to counter threats and respond to public health emergencies. During fiscal year 2016 the FDA allotted $113.3 million for such activities.
